Open AccessPB2011: CHIDAMIDE COMBINED WITH THALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (TC2D) AS AN ORAL QUADRUPLET REGIMEN FOR RELAPSED/REFRACTORY MYELOMA PATIENTS: INITIAL RESULTS OF A PHASE IIA, MULTICENTER TRIAL
Author(s) -
Li Y.,
He J.,
Han X.,
Zheng G.,
Zhang E.,
Chen Q.,
Yang Y.,
He D.,
Zhao Y.,
Fu J.,
Shou L.,
Jiang W.,
Jiang W.,
Qian S.,
Hu H.,
He H.,
Cai Z.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000850876.64075.46
Subject(s) - medicine , thalidomide , lenalidomide , regimen , dexamethasone , multiple myeloma , bortezomib , refractory (planetary science) , cyclophosphamide , phases of clinical research , oncology , gastroenterology , panobinostat , clinical trial , chemotherapy , histone deacetylase , biochemistry , chemistry , astrobiology , gene , histone , physics